A dissertation submitted to the Faculty of Science, University of the Witwatersrand, in fulfillment of the requirements for the degree Master of Science.
July, 2014 / Drosophila melanogaster, a key model organism, has cognates of over 70% of human disease genes. This has created opportunities in the development of treatments for life threatening illnesses like cancer. Mutations on the p53 tumour suppressor protein, which is an activator of apoptosis, are common in many cancers. In mammals, p53 interacts with the Retinoblastoma Binding Protein 6 (RBBP6) which enhances the activity of MDM2, the prototypical negative regulator of p53, that is absent in invertebrates. In the absence of MDM2 the Drosophila RBBP6 homolog, SNAMA, through its DWNN Catalytic Module (DCM), is suspected to play an important role in the regulation of p53, probably via the ubiquitin proteasome pathway. Through bioinformatics analyses, and experimental analysis of transcripts, this study has shown the existence of two isoforms of SNAMA named here SNAMA A and SNAMA B for the long and short isoforms, respectively. SNAMA B appears to be expressed after genotoxic stress (DNA damage) in adults as well as during embryonic development. Recombinant protein expression in bacterial and yeast systems as well as HIS-tag chromatography and Western blot analyses were used to investigate interactions with Dmp53. Due to poor expression of recombinant Dmp53 protein in both prokaryotic and eukaryotic systems and unreliable commercial antibodies, it was impossible to complete interaction studies. Overall, these studies show that the SNAMA isoforms may play important roles during development and in response to DNA damage.
Identifer | oai:union.ndltd.org:netd.ac.za/oai:union.ndltd.org:wits/oai:wiredspace.wits.ac.za:10539/15606 |
Date | 23 September 2014 |
Creators | Cajee, Umar-Faruq |
Source Sets | South African National ETD Portal |
Language | English |
Detected Language | English |
Type | Thesis |
Format | application/pdf |
Page generated in 0.0018 seconds